Efficacy of Compound Kushen Injection-Assisted Programmed Death-1 Inhibitor Combined with Docetaxel plus Cisplatin Chemotherapy in the Treatment of Non-Small Cell Lung Carcinoma
Objective:To investigate the clinical efficacy of compound Kushen injection-assisted programmed death-1(PD-1)inhibitor combined with docetaxel plus cisplatin(DP)regimen in the treatment of non-small cell lung carcinoma(NSCLC).Methods:Eighty-four patients with NSCLC treated in a hospital from October 2020 to May 2023 were retrospectively selected and divided into the control group and observation group according to the treatment regimen,with 42 patients in each group.The control group was treated with the PD-1 inhibitor combined with the DP chemotherapy,and the observation group was treated with compound Kushen injection in addition to the treatment given in the control group.The patients'clinical response in the two groups was evaluated.The levels of serum tumor markers[carcinoembryonic antigen(CEA)and tumor abnormal protein(TAP)]before and after treatment were determined in the two groups by flow cytometry.The living ability was evaluated in the two groups based on the Karnofsky performance score(KPS);The safety of the medication was evaluated based on the comparison of adverse reactions during the treatment between the two groups.Results:After treatment,the objective response rate and disease control rate were 69.05%and 95.23%in the observation group,respectively,which were higher than the figures 47.62%and 76.19%in the control group,respectively,with statistically significant difference between the two groups(P<0.05).Before treatment,there was no statistically significant difference in serum CEA and TAP levels between the two groups(P>0.05).After treatment,both CEA and TAP levels in the observation group were lower than those in the control group(P<0.05).After treatment,the KPS in the observation group was higher than that in the control group(P<0.05).In addition,in terms of adverse reactions,the incidence of myelosuppression in the observation group(30.95%)was lower than that in the control group(80.95%,P<0.05),and the total incidence of adverse reactions in the observation group(33.33%)was also lower than that in the control group(92.86%,P<0.05).Conclusion:Compared with the regimen of PD-1 inhibitor combined with DP chemotherapy,compound Kushen injection-assisted PD-1 inhibitor combined with DP chemotherapy demonstrated better clinical efficacy in the treatment of NSCLC,with significantly improved quality of life and higher safety,and thereby is recommended to be widely used in clinical practice.
万方数据
维普
